Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ørntoft T[au]:

Direct detection of early-stage cancers using circulating tumor DNA. Phallen J et al. Sci Transl Med. (2017)

An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes. Bekker-Jensen DB et al. Cell Syst. (2017)

Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. Schøler LV et al. Clin Cancer Res. (2017)

Search results

Items: 1 to 50 of 376

1.

A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy.

Strand SH, Bavafaye-Haghighi E, Kristensen H, Rasmussen AK, Hoyer S, Borre M, Mouritzen P, Besenbacher S, Orntoft TF, Sorensen KD.

Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32427. [Epub ahead of print]

PMID:
31125115
2.

[Infrastructure of clinical support and research in the Danish national genome centre].

Ørntoft TF, Brunak S, Jespergaard C, Heickendorff L, Grønkjær K, Løngreen P.

Ugeskr Laeger. 2019 Apr 1;181(7A). pii: V02190076. Danish.

PMID:
30950376
3.

A five-microRNA model (pCaP) for predicting prostate cancer aggressiveness using cell-free urine.

Fredsøe J, Rasmussen AKI, Mouritzen P, Borre M, Ørntoft T, Sørensen KD.

Int J Cancer. 2019 Mar 23. doi: 10.1002/ijc.32296. [Epub ahead of print]

PMID:
30903800
4.

Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer.

Bjerre MT, Strand SH, Nørgaard M, Kristensen H, Rasmussen AK, Mortensen MM, Fredsøe J, Mouritzen P, Ulhøi B, Ørntoft T, Borre M, Sørensen KD.

Int J Mol Sci. 2019 Mar 7;20(5). pii: E1173. doi: 10.3390/ijms20051173.

5.

Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine.

Fredsøe J, Rasmussen AKI, Laursen EB, Cai Y, Howard KA, Pedersen BG, Borre M, Mouritzen P, Ørntoft T, Sørensen KD.

Clin Chem. 2019 Apr;65(4):540-548. doi: 10.1373/clinchem.2018.296681. Epub 2019 Feb 6.

PMID:
30728149
6.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
7.

Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.

Schmidt L, Møller M, Haldrup C, Strand SH, Vang S, Hedegaard J, Høyer S, Borre M, Ørntoft T, Sørensen KD.

Br J Cancer. 2018 Dec;119(12):1527-1537. doi: 10.1038/s41416-018-0321-5. Epub 2018 Nov 19.

PMID:
30449885
8.

Contribution of allelic imbalance to colorectal cancer.

Palin K, Pitkänen E, Turunen M, Sahu B, Pihlajamaa P, Kivioja T, Kaasinen E, Välimäki N, Hänninen UA, Cajuso T, Aavikko M, Tuupanen S, Kilpivaara O, van den Berg L, Kondelin J, Tanskanen T, Katainen R, Grau M, Rauanheimo H, Plaketti RM, Taira A, Sulo P, Hartonen T, Dave K, Schmierer B, Botla S, Sokolova M, Vähärautio A, Gladysz K, Ongen H, Dermitzakis E, Bramsen JB, Ørntoft TF, Andersen CL, Ristimäki A, Lepistö A, Renkonen-Sinisalo L, Mecklin JP, Taipale J, Aaltonen LA.

Nat Commun. 2018 Sep 10;9(1):3664. doi: 10.1038/s41467-018-06132-1.

9.

Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.

Storebjerg TM, Strand SH, Høyer S, Lynnerup AS, Borre M, Ørntoft TF, Sørensen KD.

Clin Epigenetics. 2018 Aug 7;10(1):105. doi: 10.1186/s13148-018-0540-x.

10.

Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.

Schmidt L, Fredsøe J, Kristensen H, Strand SH, Rasmussen A, Høyer S, Borre M, Mouritzen P, Ørntoft T, Sørensen KD.

Ann Oncol. 2018 Sep 1;29(9):2003-2009. doi: 10.1093/annonc/mdy243.

11.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

12.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Feb;51(2):363.

13.

Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.

Haldrup C, Pedersen AL, Øgaard N, Strand SH, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Mol Oncol. 2018 Apr;12(4):545-560. doi: 10.1002/1878-0261.12183. Epub 2018 Mar 13.

14.

Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study.

Kirkegaard P, Edwards A, Nielsen TLO, Ørntoft TF, Sørensen KD, Borre M, Bro F.

BMC Fam Pract. 2018 Feb 17;19(1):32. doi: 10.1186/s12875-018-0717-6.

15.

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.

van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, Keck B, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC.

Clin Cancer Res. 2018 Apr 1;24(7):1586-1593. doi: 10.1158/1078-0432.CCR-17-2719. Epub 2018 Jan 24.

16.

Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival.

Hornshøj H, Nielsen MM, Sinnott-Armstrong NA, Świtnicki MP, Juul M, Madsen T, Sallari R, Kellis M, Ørntoft T, Hobolth A, Pedersen JS.

NPJ Genom Med. 2018 Jan 11;3:1. doi: 10.1038/s41525-017-0040-5. eCollection 2018.

17.

Founder Effect of the RETC611Y Mutation in Multiple Endocrine Neoplasia 2A in Denmark: A Nationwide Study.

Mathiesen JS, Kroustrup JP, Vestergaard P, Stochholm K, Poulsen PL, Rasmussen ÅK, Feldt-Rasmussen U, Gaustadnes M, Ørntoft TF, Rossing M, Nielsen FC, Albrechtsen A, Brixen K, Godballe C, Frederiksen AL.

Thyroid. 2017 Dec;27(12):1505-1510. doi: 10.1089/thy.2017.0404. Epub 2017 Nov 3.

PMID:
29020875
18.

Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.

Nørgaard M, Haldrup C, Storebjerg TM, Vestergaard EM, Wild PJ, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Int J Mol Sci. 2017 Sep 20;18(9). pii: E2017. doi: 10.3390/ijms18092017.

19.

Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer.

Thomsen MBH, Nordentoft I, Lamy P, Vang S, Reinert L, Mapendano CK, Høyer S, Ørntoft TF, Jensen JB, Dyrskjøt L.

Sci Rep. 2017 Sep 15;7(1):11702. doi: 10.1038/s41598-017-11291-0.

20.

A genetically inducible porcine model of intestinal cancer.

Callesen MM, Árnadóttir SS, Lyskjaer I, Ørntoft MW, Høyer S, Dagnaes-Hansen F, Liu Y, Li R, Callesen H, Rasmussen MH, Berthelsen MF, Thomsen MK, Schweiger PJ, Jensen KB, Laurberg S, Ørntoft TF, Elverløv-Jakobsen JE, Andersen CL.

Mol Oncol. 2017 Nov;11(11):1616-1629. doi: 10.1002/1878-0261.12136. Epub 2017 Oct 10.

21.

Direct detection of early-stage cancers using circulating tumor DNA.

Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA Jr, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE.

Sci Transl Med. 2017 Aug 16;9(403). pii: eaan2415. doi: 10.1126/scitranslmed.aan2415.

PMID:
28814544
22.

Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.

Fredsøe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Eur Urol Focus. 2018 Dec;4(6):825-833. doi: 10.1016/j.euf.2017.02.018. Epub 2017 Mar 9.

23.

An Optimized Shotgun Strategy for the Rapid Generation of Comprehensive Human Proteomes.

Bekker-Jensen DB, Kelstrup CD, Batth TS, Larsen SC, Haldrup C, Bramsen JB, Sørensen KD, Høyer S, Ørntoft TF, Andersen CL, Nielsen ML, Olsen JV.

Cell Syst. 2017 Jun 28;4(6):587-599.e4. doi: 10.1016/j.cels.2017.05.009. Epub 2017 Jun 7.

24.

Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.

Schøler LV, Reinert T, Ørntoft MW, Kassentoft CG, Árnadóttir SS, Vang S, Nordentoft I, Knudsen M, Lamy P, Andreasen D, Mortensen FV, Knudsen AR, Stribolt K, Sivesgaard K, Mouritzen P, Nielsen HJ, Laurberg S, Ørntoft TF, Andersen CL.

Clin Cancer Res. 2017 Sep 15;23(18):5437-5445. doi: 10.1158/1078-0432.CCR-17-0510. Epub 2017 Jun 9.

25.

Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.

Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, Keck B, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF.

Eur Urol. 2017 Sep;72(3):461-469. doi: 10.1016/j.eururo.2017.05.040. Epub 2017 Jun 2.

PMID:
28583312
26.

Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer.

Bramsen JB, Rasmussen MH, Ongen H, Mattesen TB, Ørntoft MW, Árnadóttir SS, Sandoval J, Laguna T, Vang S, Øster B, Lamy P, Madsen MR, Laurberg S, Esteller M, Dermitzakis ET, Ørntoft TF, Andersen CL.

Cell Rep. 2017 May 9;19(6):1268-1280. doi: 10.1016/j.celrep.2017.04.045.

27.

Incidence and prevalence of multiple endocrine neoplasia 2B in Denmark: a nationwide study.

Mathiesen JS, Kroustrup JP, Vestergaard P, Madsen M, Stochholm K, Poulsen PL, Krogh Rasmussen Å, Feldt-Rasmussen U, Schytte S, Pedersen HB, Hahn CH, Bentzen J, Gaustadnes M, Ørntoft TF, Hansen TVO, Nielsen FC, Brixen K, Frederiksen AL, Godballe C.

Endocr Relat Cancer. 2017 Jul;24(7):L39-L42. doi: 10.1530/ERC-17-0122. Epub 2017 Apr 24. No abstract available.

PMID:
28438782
28.

Profiling of long non-coding RNAs identifies LINC00958 and LINC01296 as candidate oncogenes in bladder cancer.

Seitz AK, Christensen LL, Christensen E, Faarkrog K, Ostenfeld MS, Hedegaard J, Nordentoft I, Nielsen MM, Palmfeldt J, Thomson M, Jensen MT, Nawroth R, Maurer T, Ørntoft TF, Jensen JB, Damgaard CK, Dyrskjøt L.

Sci Rep. 2017 Mar 24;7(1):395. doi: 10.1038/s41598-017-00327-0.

29.

epiG: statistical inference and profiling of DNA methylation from whole-genome bisulfite sequencing data.

Vincent M, Mundbjerg K, Skou Pedersen J, Liang G, Jones PA, Ørntoft TF, Dalsgaard Sørensen K, Wiuf C.

Genome Biol. 2017 Feb 21;18(1):38. doi: 10.1186/s13059-017-1168-4.

30.

Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.

Møller M, Strand SH, Mundbjerg K, Liang G, Gill I, Haldrup C, Borre M, Høyer S, Ørntoft TF, Sørensen KD.

Sci Rep. 2017 Jan 13;7:40636. doi: 10.1038/srep40636.

31.

Identifying aggressive prostate cancer foci using a DNA methylation classifier.

Mundbjerg K, Chopra S, Alemozaffar M, Duymich C, Lakshminarasimhan R, Nichols PW, Aron M, Siegmund KD, Ukimura O, Aron M, Stern M, Gill P, Carpten JD, Ørntoft TF, Sørensen KD, Weisenberger DJ, Jones PA, Duddalwar V, Gill I, Liang G.

Genome Biol. 2017 Jan 12;18(1):3. doi: 10.1186/s13059-016-1129-3.

32.

Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.

Christensen E, Birkenkamp-Demtröder K, Nordentoft I, Høyer S, van der Keur K, van Kessel K, Zwarthoff E, Agerbæk M, Ørntoft TF, Jensen JB, Dyrskjøt L.

Eur Urol. 2017 Jun;71(6):961-969. doi: 10.1016/j.eururo.2016.12.016. Epub 2017 Jan 6.

PMID:
28069289
33.

RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.

Strand SH, Switnicki M, Moller M, Haldrup C, Storebjerg TM, Hedegaard J, Nordentoft I, Hoyer S, Borre M, Pedersen JS, Wild PJ, Park JY, Orntoft TF, Sorensen KD.

Oncotarget. 2017 Jan 24;8(4):5774-5788. doi: 10.18632/oncotarget.14391.

34.

FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.

Beukers W, van der Keur KA, Kandimalla R, Vergouwe Y, Steyerberg EW, Boormans JL, Jensen JB, Lorente JA, Real FX, Segersten U, Orntoft TF, Malats N, Malmström PU, Dyrskjot L, Zwarthoff EC.

J Urol. 2017 Jun;197(6):1410-1418. doi: 10.1016/j.juro.2016.12.096. Epub 2016 Dec 31.

PMID:
28049011
35.

SNHG5 promotes colorectal cancer cell survival by counteracting STAU1-mediated mRNA destabilization.

Damas ND, Marcatti M, Côme C, Christensen LL, Nielsen MM, Baumgartner R, Gylling HM, Maglieri G, Rundsten CF, Seemann SE, Rapin N, Thézenas S, Vang S, Ørntoft T, Andersen CL, Pedersen JS, Lund AH.

Nat Commun. 2016 Dec 22;7:13875. doi: 10.1038/ncomms13875.

36.

Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.

Mathiesen JS, Kroustrup JP, Vestergaard P, Stochholm K, Poulsen PL, Rasmussen ÅK, Feldt-Rasmussen U, Gaustadnes M, Ørntoft TF, van Overeem Hansen T, Nielsen FC, Brixen K, Godballe C, Frederiksen AL.

Thyroid. 2017 Feb;27(2):215-223. doi: 10.1089/thy.2016.0411. Epub 2017 Jan 13.

37.

Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect.

Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A, Leal L, Wahi JE, Setien-Baranda F, Szczesna K, Moutinho C, Martinez-Cardus A, Heyn H, Sandoval J, Puertas S, Vidal A, Sanjuan X, Martinez-Balibrea E, Viñals F, Perales JC, Bramsem JB, Ørntoft TF, Andersen CL, Tabernero J, McDermott U, Boxer MB, Vander Heiden MG, Albar JP, Esteller M.

Nat Commun. 2016 Nov 2;7:13467. doi: 10.1038/ncomms13467. No abstract available.

38.

Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.

van Kessel KE, Beukers W, Lurkin I, Ziel-van der Made A, van der Keur KA, Boormans JL, Dyrskjøt L, Márquez M, Ørntoft TF, Real FX, Segersten U, Malats N, Malmström PU, Van Criekinge W, Zwarthoff EC.

J Urol. 2017 Mar;197(3 Pt 1):590-595. doi: 10.1016/j.juro.2016.09.118. Epub 2016 Oct 13.

PMID:
27746284
39.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG.

Oncotarget. 2016 Nov 15;7(46):74734-74746. doi: 10.18632/oncotarget.12543.

40.

Widespread DNA hypomethylation and differential gene expression in Turner syndrome.

Trolle C, Nielsen MM, Skakkebæk A, Lamy P, Vang S, Hedegaard J, Nordentoft I, Ørntoft TF, Pedersen JS, Gravholt CH.

Sci Rep. 2016 Sep 30;6:34220. doi: 10.1038/srep34220.

41.

Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.

Thomsen MB, Nordentoft I, Lamy P, Høyer S, Vang S, Hedegaard J, Borre M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Mol Oncol. 2016 Nov;10(9):1450-1460. doi: 10.1016/j.molonc.2016.08.003. Epub 2016 Aug 17.

42.

miRNA profiling of circulating EpCAM(+) extracellular vesicles: promising biomarkers of colorectal cancer.

Ostenfeld MS, Jensen SG, Jeppesen DK, Christensen LL, Thorsen SB, Stenvang J, Hvam ML, Thomsen A, Mouritzen P, Rasmussen MH, Nielsen HJ, Ørntoft TF, Andersen CL.

J Extracell Vesicles. 2016 Aug 29;5:31488. doi: 10.3402/jev.v5.31488. eCollection 2016.

43.

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells.

Rasmussen MH, Lyskjær I, Jersie-Christensen RR, Tarpgaard LS, Primdal-Bengtson B, Nielsen MM, Pedersen JS, Hansen TP, Hansen F, Olsen JV, Pfeiffer P, Ørntoft TF, Andersen CL.

Nat Commun. 2016 Aug 16;7:12436. doi: 10.1038/ncomms12436.

44.

Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma.

Lamy P, Nordentoft I, Birkenkamp-Demtröder K, Thomsen MB, Villesen P, Vang S, Hedegaard J, Borre M, Jensen JB, Høyer S, Pedersen JS, Ørntoft TF, Dyrskjøt L.

Cancer Res. 2016 Oct 1;76(19):5894-5906. Epub 2016 Aug 3.

45.

Ectodermal dysplasia with immunodeficiency caused by a branch-point mutation in IKBKG/NEMO.

Jørgensen SE, Bøttger P, Kofod-Olsen E, Holm M, Mørk N, Ørntoft TF, Sørensen UBS, Bernth-Jensen JM, Herlin T, Veirum J, Larsen CS, Østergaard L, Hartmann R, Christiansen M, Mogensen TH.

J Allergy Clin Immunol. 2016 Dec;138(6):1706-1709.e4. doi: 10.1016/j.jaci.2016.05.030. Epub 2016 Jun 29. No abstract available.

PMID:
27477329
46.

SNHG16 is regulated by the Wnt pathway in colorectal cancer and affects genes involved in lipid metabolism.

Christensen LL, True K, Hamilton MP, Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen JB, Pedersen JS, Lund AH, Vang S, Stribolt K, Madsen MR, Laurberg S, McGuire SE, Ørntoft TF, Andersen CL.

Mol Oncol. 2016 Oct;10(8):1266-82. doi: 10.1016/j.molonc.2016.06.003. Epub 2016 Jun 26.

47.

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MBH, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N, Borre M, Hartmann A, Stöhr R, Wach S, Keck B, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KEM, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

Cancer Cell. 2016 Jul 11;30(1):27-42. doi: 10.1016/j.ccell.2016.05.004. Epub 2016 Jun 16.

48.

Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.

Kristensen H, Thomsen AR, Haldrup C, Dyrskjøt L, Høyer S, Borre M, Mouritzen P, Ørntoft TF, Sørensen KD.

Oncotarget. 2016 May 24;7(21):30760-71. doi: 10.18632/oncotarget.8953.

49.

Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.

Haldrup C, Lynnerup AS, Storebjerg TM, Vang S, Wild P, Visakorpi T, Arsov C, Schulz WA, Lindberg J, Grönberg H, Egevad L, Borre M, Ørntoft TF, Høyer S, Sørensen KD.

Mol Oncol. 2016 Jun;10(6):825-37. doi: 10.1016/j.molonc.2016.02.001. Epub 2016 Feb 9.

50.

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.

Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Høyer S, Reinert T, Vang S, Borre M, Agerbæk M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Eur Urol. 2016 Jul;70(1):75-82. doi: 10.1016/j.eururo.2016.01.007. Epub 2016 Jan 20.

PMID:
26803478

Supplemental Content

Loading ...
Support Center